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1. Introduction
Polycystic ovarian syndrome (PCOS) is a common 
endocrine and metabolic disorder in women of 
reproductive age, which is characterized by ovulatory 
dysfunction, hyperandrogenism, and polycystic ovaries 
(1). PCOS is known to be related to increased insulin 
resistance, obesity, type II diabetes, and cardiovascular 
diseases (2). Different theories have been proposed for the 
pathogenesis of PCOS; one of the major hypotheses is the 
insulin theory. According to this theory, insulin resistance 
and its resultant compensatory hyperinsulinemia are 
thought be etiologic factors of this syndrome and its 
related complications (3–6). Insulin resistance and 
hyperinsulinemia are known to disturb nitric oxide-
mediated vasodilatation and endothelial functions, which 
results in vascular damage and leads to increased risk for 
long-term metabolic disorders. 
The homeostasis model assessment of insulin resistance 
(HOMA-IR) is an alternative tool to the glucose clamp for 
the evaluation of insulin resistance by using the fasting 
glucose and insulin levels of patients. It is commonly used, 
especially for investigations including a large number of 
subjects.
N-Dimethyl-L-arginine is an inhibitor of nitric 
oxide synthase and is also known as asymmetric 
dimethylarginine (ADMA) (7). It is synthesized by the 
action of the protein arginine methyltransferases and is 
eliminated by renal excretion or by the enzymatic action 
of dimethylarginine dimethylaminohydrolase (DDAH). 
High ADMA values inhibit nitric oxide (NO) production 
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and generate superoxides. However, NO is needed to 
promote vasodilation. ADMA is considered to be a marker 
of endothelial dysfunction because of the relation between 
ADMA and NO metabolism. High levels of ADMA in 
human plasma are associated with cardiovascular and 
metabolic diseases (8). Therefore, the strong association 
between PCOS and insulin resistance, diabetes, obesity, 
and cardiovascular disease, which are almost always found 
in conjunction with endothelial dysfunction, makes the 
relationship of PCOS and ADMA important.
The aim of this study was to find out whether there is 
any correlation between insulin resistance and NO-related 
endothelial dysfunction in patients with PCOS. 
2. Materials and methods
Following local ethics board approval (19.12.2005/346), 
a total of 25 patients with PCOS and 25 healthy female 
volunteers were included in the study. The diagnosis of 
PCOS was done according to the 2003 Rotterdam Criteria 
(9). Patients who had received steroid or sex hormones in the 
previous 6 months or any medication related to hirsutism; 
patients with hyperprolactinemia, congenital adrenal 
hyperplasia (or with high 17α-hydroxyprogesterone), 
Cushing’s syndrome, thyroid diseases, functional tumors 
that may cause hyperandrogenemia, hypertension, glucose 
intolerance, or diabetes; and smokers were all excluded 
from the study. 
The control group was composed of volunteers 
with normal ovarian ultrasound findings and with no 
hormonal, metabolic, and cardiovascular diseases or 
menstrual irregularities. Smokers were also excluded from 
the control group. The anthropometric measurements of 
both groups were recorded. 
The blood samples of subjects of both groups were 
obtained on days 3–5 of their menstrual cycles. The 
sampling was performed around 0900 hours after 8–10 
h of overnight fasting. These fasting venous blood 
samples were used for the analyses of glucose, insulin, 
free testosterone, dehydroepiandrostenedione (DHEA), 
follicle-stimulating hormone (FSH), luteinizing hormone 
(LH), estradiol, prolactin (PRL), 17-hydroxyprogesterone, 
total cholesterol, triglycerides, high-density lipoprotein 
cholesterol (HDL-C), ADMA, and NO. 
The oral glucose tolerance test was performed by giving 
75 g of glucose. Blood samples were taken at time intervals 
of 0 and 120 min. HOMA-IR was calculated as [(fasting 
glucose × fasting insulin) / 405]. Serum low-density 
lipoprotein (LDL) cholesterol levels were calculated by 
using the Friedewald formula [LDL-C = total cholesterol 
– (HDL-C + triglyceride / 5)].
Glucose levels were measured by autoanalyzer 
(Abbott Aeroset, Toshiba, Japan) with the adapted 
hexokinase method. Serum cholesterol measurements 
were performed with an autoanalyzer (Abbott Aeroset, 
Toshiba) adapted for cholesterol esterase. Serum HDL 
levels were determined using the photometric elimination 
method (Abbott Aeroset, Toshiba). Serum triglyceride 
levels were measured by autoanalyzer (Abbott Aeroset, 
Toshiba) and an adapted photometric method. Serum LH, 
FSH, PRL, insulin, and DHEA levels were measured with 
commercially available chemiluminescence kits (Abbott 
Architect, Toshiba). Serum estradiol, free testosterone, 
and 17-hydroxyprogesterone levels were measured by 
radioimmunoassay (RIA) method (DSL RIA Kits, Webster, 
TX, USA). Serum NO levels of both the control and study 
groups were measured using the diazotization method, 
which is based on the Griess reaction (10). NO values are 
expressed as µmol/L. Plasma ADMA concentrations were 
measured by high-performance liquid chromatography 
method, which was described by Chen et al. (11). ADMA 
values are expressed as µmol/L.
2.1. Statistical analyses 
All data were recorded as mean ± SD and median 
(minimum–maximum). Statistical analyses were 
performed with SPSS 10.01 for Windows. Using the 
Kolmogorov–Smirnov test, each variable was evaluated for 
relevance to normal distribution. For the variables relevant 
to normal distribution, a t-test was used for comparison 
of the study and control groups. For variables not relevant 
to normal distribution, the Mann–Whitney U test was 
used for comparison of variables. The Shapiro–Wilk test 
was also used. Correlation coefficients were calculated 
with Pearson and Spearman correlation tests. P < 0.05 was 
accepted to be statistically significant. 
3. Results
The mean age and mean body mass index (BMI) of the 
study group were 24.64 ± 4.93 (range: 19–36) years and 
26.35 ± 7.05 (range: 16.48–39.55) kg/m2, respectively. The 
mean age of the control group was 26.32 ± 3.89 (range: 
20–34) years and the mean BMI of the control group was 
22.46 ± 3.43 (17.10–29.06) kg/m2. 
Our results showed that the mean HOMA-IR rates of 
patients with PCOS were significantly higher than those of 
the control group (P = 0.001). We also found statistically 
higher ADMA levels in the PCOS group (P = 0.001). 
However, the NO concentrations were significantly lower 
in the PCOS patients (P = 0.008). In terms of the other 
serum parameters measured in the present study, no 
statistically significant alterations were detected between 
the study and control groups. The data obtained from the 
study are summarized in Tables 1 and 2. 
Measurements of correlations among HOMA-IR, 
ADMA, and NO showed no significant correlations 
between the variables. 
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4. Discussion
The relationships between PCOS and obesity, insulin 
resistance, endothelial dysfunction, and endothelial 
dysfunction-related cardiovascular risks have complex 
features. Endothelial dysfunction is not only an early and 
reversible indicator of vascular anomalies, but it is also a 
diagnostic indicator of late cardiovascular morbidity (12). 
Insulin resistance in PCOS is both a reason and a result, 
which affects nearly 50%–70% of the PCOS patients. 
Pamuk et al. found higher HOMA-IR levels but no 
significant differences in ADMA levels in the PCOS group 
compared to the control group (13). A cardiovascular 
study done in Quebec showed that hyperinsulinemia is 
an independent risk factor of cardiovascular diseases 
Table 1. Comparison of routine data of the groups.
Study group Control group
P
Mean ± SD Median(min–max) Mean ± SD
Median
(min–max)
Age 
(years) 24.64 ± 4.93
23.00
(19.00–36.00) 26.32 ± 3.89
26.00
(20.00–34.00) †0.188
BMI 
(kg / m2) 26.35 ± 7.05
24.40
(16.48–39.55) 22.46 ± 3.43
21.32
(17.10–29.06) ‡0.510
HDL-C 
(mg/dL) 46.36 ± 7.66
45.00
(34.00–68.00) 43.04 ± 7.80
43.00
(30.00–63.00) ‡0.075
Triglyceride 
(mg/dL) 100.00 ± 48.63
83.00
(37.00–185.00) 98.24 ± 35.29
96.00
(44.00–178.00) †0.884
Total cholesterol
(mg/dL) 159.56 ± 28.93
167.00
(75.00–195.00) 150.44 ± 22.54
148.00
(110.00–185.00) ‡0.121
LDL-C 
(mg/dL) 96.04 ± 20.87
97.00
(52.00–127.00) 88.88 ± 20.13
87.00
(55.00–120.00) †0.223
Glucose 
(mg/dL) 90.48 ± 7.60
90.00
(80.00–103.00) 88.24 ± 10.26
89.00
(70.00–105.00) †0.385
Insulin 
(U/mL) 12.27 ± 5.88
11.40
(3.39–26.20) 6.92 ± 2.71
6.30
(3.30–15.70) †0.001*
‡: Mann–Whitney U test, †: t-test, * P < 0.05.
BMI: Body mass index, HDL-C: high-density-lipoprotein cholesterol, LDL-C: low-density lipoprotein cholesterol.
Table 2. Comparison of HOMA-IR, plasma ADMA, and serum NO levels of the groups.
Study group Control Group
P
Mean ± SD Median(min–max) Mean ± SD
Median
(min–max)
HOMA-IR 2.76 ± 1.37 2.65(0.79–6.10) 1.52 ± 0.66
1.42
(0.64–3.30) ‡0.001*
ADMA
(µmol/L) 1.20 ± 0.47
1.07
(0.43–2.51) 0.75 ± 0.45
0.73
(0.28–2.27) ‡0.001*
NO
(µmol/L) 10.66 ± 9.55
5.99
(0.49–35.74) 25.85 ± 24.96
16.23
(2.74–105.73) ‡0.008*
‡: Mann–Whitney U test, * P < 0.05.
HOMA-IR: Homeostasis assessment model insulin resistance, ADMA: asymmetric dimethyl arginine, NO: nitric oxide.
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(14). HOMA-IR levels of the PCOS group measured in 
the present study were significantly higher than those of 
the control group. Furthermore, we could not find any 
correlation between HOMA-IR levels and BMI or the age 
of the PCOS patients. Obesity is a risk factor for insulin 
resistance. However, results of the present study indicate 
that increased insulin resistance in PCOS patients may 
be due to the additional risk factors. Further studies are 
needed to find these putative risk factors.  
Endothelium regulates the vascular tonus by secreting 
vasodilators, such as NO, and vasoconstrictors, such as 
endothelin (15). In the presence of insulin resistance, the 
relation between insulin and NO production is disturbed 
(16). Mather et al. showed normal endothelial functions 
in PCOS patients (17). However, Paradisi et al. reported 
endothelial dysfunction and insulin resistance in women 
with PCOS (18). Orio et al. evaluated young PCOS 
patients with no metabolic and cardiovascular disease 
and reported disturbances in endothelial functions 
in the early period of the disease (19). Sorensen et al. 
showed that endothelial dysfunction in PCOS patients is 
independent from age, BMI, and total cholesterol levels 
(12). In our study, serum NO levels of women with PCOS 
were significantly lower than those of healthy women. 
Low levels of serum NO may show an endothelial 
dysfunction. Thus, our results are in accordance with the 
findings of previous researchers.
There are several studies showing a strong correlation 
between increased ADMA levels and cardiovascular 
mortality and morbidity (7,20,21). These findings suggest 
that ADMA is not only an indicator of cardiovascular 
disease but also that it plays a role in the etiopathogenesis 
of the disease. In a recent metaanalysis, Toulis et al. 
showed increased cardiovascular disease risk markers 
in women with PCOS (22). They also demonstrated that 
ADMA levels were significantly elevated in the PCOS 
group (22). Moran et al. found increased ADMA levels 
in women with PCOS, independent of age and adiposity 
(23). Choi et al. suggested that nonobese women with 
PCOS are at an increased risk for cardiovascular diseases. 
They also showed increased ADMA levels in the PCOS 
group (24). In our study, PCOS patients were found 
to have significantly higher plasma ADMA levels. 
These high levels of ADMA may be explained by 
endothelial dysfunction caused by insulin resistance. The 
incidence of hypercholesterolemia, hyperglycemia, and 
hyperhomocysteinemia is higher in PCOS patients than 
in normal controls. These pathologic conditions may 
inhibit the enzyme DDAH, which metabolizes ADMA, 
and cause an increase in ADMA levels. Ngo et al. showed 
increased ADMA levels with low NO responsiveness 
(25). However, in our study, we found no correlation 
between ADMA and NO levels. This difference may be 
due to the low number of the PCOS patients enrolled in 
this study. 
Studies showed that a high-fat diet also causes an 
increase in plasma ADMA levels (26). It was shown that, 
in hypercholesterolemic rabbits, DDAH activity in both 
vascular and nonvascular tissues is decreased and plasma 
ADMA levels are increased (27). Chan et al. showed that 
mononuclear cell adhesion in hypercholesterolemic 
patients has a high correlation with plasma ADMA 
concentrations (28). In cell cultures, the adhesion of these 
cells is increased by the addition of ADMA-stimulated 
vascular cells to the culture. In our study, there was no 
dyslipidemia in the PCOS patients, and there was no 
difference between the study and control groups in terms 
of blood lipid parameters. Thus, we were able to exclude 
the effect of high lipid levels on ADMA concentrations. 
In conclusion, we found that there is significant insulin 
resistance in PCOS patients, independently of age, BMI, 
and blood lipid profile. Altered ADMA and NO levels 
in PCOS patients indicate the presence of endothelial 
dysfunction. However, no correlation was detected 
between HOMA-IR as an insulin resistance determinant 
and altered ADMA and NO levels, which may show that 
there are additional mechanisms of cardiovascular risks in 
PCOS other than insulin resistance. 
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